General MM

When should MRD status be used in clinical decision making in MM?

L: English

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Elisabet E. Manasanch, MD Anderson Cancer Center, Houston, US, answers the question: When should we test for minimal residual in clinical practice of multiple myeloma?

Elisabet Manasanch discusses the use of minimal residual disease (MRD) status to guide patient treatment choices, she explains MRD is currently being used to evaluate patient response and to monitor relapse.